[Discussion] regulatory status changed in several countries and nobody noticed
Posting this as a discussion rather than a claim: regulatory status changed in several countries and nobody noticed.
Regulatory classification differs between jurisdictions and has changed in several of them recently. Any answer to a status question needs a place and a date attached.
Short peptides in solution are subject to hydrolysis and, depending on sequence, oxidation. Storage state and time in solution are practical variables that this board almost never discusses.
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Corrections welcome, especially the pedantic ones. Pedantry is how this board earns its reputation.
best — the order this archive was captured in
It is a fifteen-residue peptide with a published sequence, which makes synthesis straightforward and makes identity verification the meaningful test rather than an optional extra.
Agreed — cheap to make is a double-edged fact and it explains a lot about this corner of the market.
That claim traces back to a single preclinical paper that says something considerably narrower.
Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read.